Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC Gemcitabine for Pancreatic Carcinomatosis
NCT03251365Phase 3Unknown
- Sponsor
- Hospital General Universitario Ciudad Real
- Start
- Jul 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Hospital General Universitario Ciudad Real. Primary endpoints: Morbidity at 30 days and Overall Survival at 5 years. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03251365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03251365.